Meeting NewsVideo

VIDEO: FMT safety in pediatric C. diff infection

CHICAGO — In this exclusive video perspective from the NASPGHAN Annual Meeting, Richard Kellermayer, MD, PhD, medical director of the pediatric inflammatory bowel disease center at the Baylor College of Medicine, Texas Children’s Hospital, discusses his presentation on guidelines and safety in fecal microbiota transplantation for children with recurrent Clostridioides difficile infection.

“There are new regulations recommended by the [FDA] that really highlight that donors should be screened for multiple-drug resistant organisms,” he told Healio Gastroenterology and Liver Disease. “That really has not been done before July 2019.”

Kellermayer also provided guidance on which patients would be good candidates for FMT. The best candidates are patients who had more than three recurrent episodes of C. diff infection that were mild or moderate who failed or recurred after treatment within 8 weeks, according to Kellermayer.

In his presentation, Kellermayer also discussed some of the other indications of FMT currently under exploration by researchers.

“Those require investigational drug approval by the FDA,” he said.

Reference:

Kellermayer R. “Fecal Microbiota Transplantation in the XXI. Century, Really?” Presented at: NASPGHAN Annual Meeting; Oct. 17-19, 2019; Chicago.

Disclosures: Kellermayer reports no relevant financial disclosures.

CHICAGO — In this exclusive video perspective from the NASPGHAN Annual Meeting, Richard Kellermayer, MD, PhD, medical director of the pediatric inflammatory bowel disease center at the Baylor College of Medicine, Texas Children’s Hospital, discusses his presentation on guidelines and safety in fecal microbiota transplantation for children with recurrent Clostridioides difficile infection.

“There are new regulations recommended by the [FDA] that really highlight that donors should be screened for multiple-drug resistant organisms,” he told Healio Gastroenterology and Liver Disease. “That really has not been done before July 2019.”

Kellermayer also provided guidance on which patients would be good candidates for FMT. The best candidates are patients who had more than three recurrent episodes of C. diff infection that were mild or moderate who failed or recurred after treatment within 8 weeks, according to Kellermayer.

In his presentation, Kellermayer also discussed some of the other indications of FMT currently under exploration by researchers.

“Those require investigational drug approval by the FDA,” he said.

Reference:

Kellermayer R. “Fecal Microbiota Transplantation in the XXI. Century, Really?” Presented at: NASPGHAN Annual Meeting; Oct. 17-19, 2019; Chicago.

Disclosures: Kellermayer reports no relevant financial disclosures.

    See more from North American Society For Pediatric Gastroenterology, Hepatology & Nutrition